Target intelligence / Profile preview

Endometrial modification

Molecular classification
Other (not a molecule, receptor, enzyme, transporter, or related target)
01

Overview

Endometrial modification" describes the cyclical physiological changes that occur in the endometrium—the uterine lining—throughout the menstrual cycle. This remodeling is primarily governed by the interplay of estrogen and progesterone: estrogen promotes endometrial proliferation and thickening, peaking before ovulation, while progesterone induces differentiation, glandular transformation, secretory activity, and receptivity for embryo implantation post-ovulation. This process is crucial for normal fertility and supported pregnancy. Abnormal endometrial modification, such as insufficient or excessive response to hormonal signals, is implicated in disorders such as infertility, recurrent implantation failure, endometrial hyperplasia, and carcinoma. Therapeutically, hormones such as progestins may be used to modulate or restore normal endometrial function, particularly in cases of hyperplasia or preparation for assisted reproduction[1][5][7]. Because "endometrial modification" is a process—not a target molecule or receptor—none of the canonical fields for molecular targets apply. If seeking information about specific molecules mediating endometrial changes (such as estrogen receptor, progesterone receptor, etc.), those targets should be referenced directly by their molecular names.

Other names
Endometrial remodelingEndometrial transformationEndometrial receptivity
02

Mechanism of action

Modulation of estrogen and progesterone activity on endometrial tissue[1][5][7] Influence on hormone receptor signaling pathways

03

Biological functions

Preparation for embryo implantationMenstrual cycle regulationTissue remodelingRegulation of endometrial receptivity
04

Disease associations

Infertility (due to inadequate modification)Implantation failureEndometrial hyperplasia (in abnormal modification)Endometrial cancer (in maladaptive processes)Other
05

Safety considerations

Excessive estrogen without adequate progesterone can lead to endometrial hyperplasia and increased cancer risk[1][5][7]Hormone therapies may raise risk of abnormal uterine bleeding or endometrial pathologyInadequate endometrial modification leads to infertility or pregnancy loss
06

Interacting drugs

Progesterone

3 more in the full profile.

07

Biomarkers

Estradiol (E2)Progesterone receptor (PR)Estrogen receptor (ER)Endometrial thickness (ultrasound measurement)Proliferation markers in endometrial biopsy

Beyond the preview

Go deeper on Endometrial modification.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endometrial modification.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call